[go: up one dir, main page]

ZA9610299B - Pyrazole derivatives process for their preparation and pharmaceutical compositions in which they are present - Google Patents

Pyrazole derivatives process for their preparation and pharmaceutical compositions in which they are present

Info

Publication number
ZA9610299B
ZA9610299B ZA9610299A ZA9610299A ZA9610299B ZA 9610299 B ZA9610299 B ZA 9610299B ZA 9610299 A ZA9610299 A ZA 9610299A ZA 9610299 A ZA9610299 A ZA 9610299A ZA 9610299 B ZA9610299 B ZA 9610299B
Authority
ZA
South Africa
Prior art keywords
preparation
present
pharmaceutical compositions
pyrazole derivatives
derivatives process
Prior art date
Application number
ZA9610299A
Other languages
English (en)
Inventor
Francis Barth
Pierre Casellas
Joseph Millan
Didier Oustric
Murielle Rinaldi
Martine Sarran
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA9610299B publication Critical patent/ZA9610299B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA9610299A 1995-12-08 1996-12-06 Pyrazole derivatives process for their preparation and pharmaceutical compositions in which they are present ZA9610299B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9514547A FR2742148B1 (fr) 1995-12-08 1995-12-08 Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
ZA9610299B true ZA9610299B (en) 1997-06-18

Family

ID=9485291

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610299A ZA9610299B (en) 1995-12-08 1996-12-06 Pyrazole derivatives process for their preparation and pharmaceutical compositions in which they are present

Country Status (34)

Country Link
US (1) US5925768A (et)
EP (2) EP0885889A3 (et)
JP (1) JP3510270B2 (et)
KR (1) KR100488610B1 (et)
CN (1) CN1101813C (et)
AR (1) AR004364A1 (et)
AT (1) ATE191211T1 (et)
AU (1) AU718763B2 (et)
BR (1) BR9611986A (et)
CA (1) CA2239489C (et)
CZ (1) CZ294307B6 (et)
DE (1) DE69607484T2 (et)
DK (1) DK0868420T3 (et)
EE (1) EE04674B1 (et)
ES (1) ES2148820T3 (et)
FR (1) FR2742148B1 (et)
GR (1) GR3033626T3 (et)
HU (1) HUP9901244A3 (et)
IL (1) IL124801A (et)
IS (1) IS4765A (et)
MX (1) MX9804565A (et)
MY (1) MY115228A (et)
NO (1) NO310683B1 (et)
NZ (1) NZ323962A (et)
PL (1) PL186466B1 (et)
PT (1) PT868420E (et)
RU (1) RU2170230C2 (et)
SI (1) SI0868420T1 (et)
SK (1) SK283706B6 (et)
TR (1) TR199801041T2 (et)
TW (1) TW402594B (et)
UA (1) UA44913C2 (et)
WO (1) WO1997021682A1 (et)
ZA (1) ZA9610299B (et)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0979228A4 (en) * 1997-03-18 2000-05-03 Smithkline Beecham Corp CANNABINOID RECEPTOR AGONISTS
EP1075470B1 (en) * 1998-05-04 2003-08-13 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
CN1561990A (zh) 1999-03-22 2005-01-12 免疫力药品有限公司 治疗免疫疾病
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
WO2001029007A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
WO2001028329A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Peripheral cannabinoid receptor (cb2) selective ligands
FR2800372B1 (fr) * 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US7329651B2 (en) * 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
ATE478670T1 (de) 2001-01-29 2010-09-15 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
EP1414775B1 (en) * 2001-07-13 2012-12-19 The University of Connecticut Bicyclic cannabinoid
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2005507875A (ja) * 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
CA2464333C (en) * 2001-10-26 2011-07-26 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
HUP0401924A3 (en) * 2001-11-14 2009-07-28 Schering Corp Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
WO2003061699A1 (en) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedies for allergic diseases
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
US7217732B2 (en) 2002-06-19 2007-05-15 Schering Corporation Cannabinoid receptor agonists
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
JP2005539036A (ja) * 2002-08-21 2005-12-22 グラクソ　グループ　リミテッド ピリミジン化合物
WO2004017922A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
GB0222495D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
JP2006506366A (ja) * 2002-10-18 2006-02-23 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用方法
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CA2506895A1 (en) 2002-11-25 2004-06-10 Schering Corporation Cannabinoid receptor ligands
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
ATE450505T1 (de) * 2003-01-02 2009-12-15 Hoffmann La Roche Cb 1 rezeptor inversagonisten
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2004078261A1 (en) * 2003-03-07 2004-09-16 The University Court Of The University Of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
MXPA05011922A (es) * 2003-05-07 2006-02-17 Pfizer Prod Inc Ligandos del receptor de cannabinoides y sus usos.
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402357D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
US20080261977A1 (en) * 2004-02-23 2008-10-23 Andrew John Eatherton Pyrimidine Derivatives as Cannabinoid Receptor Modulators
ATE407119T1 (de) * 2004-02-24 2008-09-15 Glaxo Group Ltd Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
ATE444066T1 (de) * 2004-06-22 2009-10-15 Schering Corp Liganden für den cannabinoidrezeptoren
EP2343302A1 (en) 2004-07-12 2011-07-13 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
AP2007004024A0 (en) * 2004-11-29 2007-06-30 Warner Lambert Co Therapeutic pyrazoloÄ3,4-BÜpyridines and indazoles
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
EP2368881A1 (en) * 2005-01-10 2011-09-28 University of Connecticut Heteropyrazole analogs acting on cannabinoid receptors
FR2887550A1 (fr) * 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
AU2007226673A1 (en) * 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
US20070254863A1 (en) * 2006-04-27 2007-11-01 Jochen Antel Use of CBx cannabinoid receptor modulators as potassium channel modulators
US7763607B2 (en) * 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
AU2007245733A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBX cannabinoid receptor modulators and Potassium channel modulators
US7875647B2 (en) * 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
NZ578063A (en) 2006-12-18 2011-09-30 7Tm Pharma As Cannabinoid CB1 receptor modulators
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
EP1985295A1 (en) 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
CN101314591B (zh) * 2007-05-30 2010-09-29 上海阳帆医药科技有限公司 吡唑类高选择性大麻受体-1拮抗剂和/或反向激动剂
FR2916758B1 (fr) * 2007-06-04 2009-10-09 Sanofi Aventis Sa Derives de 1-benzylpyrazole, leur preparation et leur application en therapeutique
PT2176208E (pt) * 2007-07-30 2015-05-11 Zynerba Pharmaceuticals Inc Pró-fármacos de canabidiol, composições compreendendo pró- fármacos de canabidiol e métodos de utilização dos mesmos
WO2009029727A1 (en) * 2007-08-28 2009-03-05 Vanderbilt University Cannabinoid receptor targeted agent
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
KR20100072037A (ko) * 2007-09-20 2010-06-29 애보트 헬스케어 프로덕츠 비.브이. 칸나비노이드 ｃｂ₁수용체 효능제로서의 5-아릴-4,5-디하이드로-(1ｈ)-피라졸
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
EP2311443A1 (en) 2009-10-15 2011-04-20 Rheinische Friedrich-Wilhelms-Universität Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
CN102329192A (zh) * 2011-09-30 2012-01-25 山东天一化学股份有限公司 溴化苄的合成方法
CN106459004B (zh) * 2014-06-06 2020-09-15 研究三角协会 爱帕琳肽受体(apj)激动剂及其用途
CA2988983A1 (en) 2015-06-12 2016-12-15 Vettore, LLC Mct4 inhibitors for treating disease
JP7123929B2 (ja) 2016-12-12 2022-08-23 ベットーレ リミテッド ライアビリティー カンパニー Ｍｃｔ４の複素環阻害剤
US10420089B2 (en) 2017-08-10 2019-09-17 At&T Intellectual Property I, L.P. Adaptive two-stage downlink control channel structure for code block group based fifth generation (5G) or other next generation systems
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
US12054480B2 (en) 2020-07-31 2024-08-06 Makscientific, Llc Compounds for treating cannabinoid toxicity and acute cannabinoid overdose

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
NZ323962A (en) 1999-05-28
IL124801A0 (en) 1999-01-26
PT868420E (pt) 2000-08-31
TR199801041T2 (xx) 1998-08-21
HUP9901244A2 (hu) 1999-08-30
HUP9901244A3 (en) 2000-12-28
DE69607484D1 (de) 2000-05-04
JP3510270B2 (ja) 2004-03-22
UA44913C2 (uk) 2002-03-15
CN1101813C (zh) 2003-02-19
PL186466B1 (pl) 2004-01-30
BR9611986A (pt) 1999-02-17
EP0885889A3 (fr) 1999-01-27
SK283706B6 (sk) 2003-12-02
NO310683B1 (no) 2001-08-13
SK75898A3 (en) 1999-01-11
CZ294307B6 (cs) 2004-11-10
IL124801A (en) 2004-07-25
FR2742148B1 (fr) 1999-10-22
GR3033626T3 (en) 2000-10-31
NO982589D0 (no) 1998-06-05
EE04674B1 (et) 2006-08-15
EE9800171A (et) 1998-12-15
ATE191211T1 (de) 2000-04-15
RU2170230C2 (ru) 2001-07-10
EP0868420A1 (fr) 1998-10-07
CA2239489C (en) 2006-05-09
MY115228A (en) 2003-04-30
DK0868420T3 (da) 2000-08-21
SI0868420T1 (en) 2000-10-31
FR2742148A1 (fr) 1997-06-13
KR19990072004A (ko) 1999-09-27
CN1207731A (zh) 1999-02-10
PL327177A1 (en) 1998-11-23
CA2239489A1 (en) 1997-06-19
IS4765A (is) 1998-06-08
AU718763B2 (en) 2000-04-20
US5925768A (en) 1999-07-20
KR100488610B1 (ko) 2005-09-26
WO1997021682A1 (fr) 1997-06-19
DE69607484T2 (de) 2000-10-26
AU1101097A (en) 1997-07-03
EP0885889A2 (fr) 1998-12-23
MX9804565A (es) 1998-09-30
AR004364A1 (es) 1998-11-04
NO982589L (no) 1998-08-03
JP2000502080A (ja) 2000-02-22
EP0868420B1 (fr) 2000-03-29
CZ177598A3 (cs) 1998-10-14
TW402594B (en) 2000-08-21
ES2148820T3 (es) 2000-10-16

Similar Documents

Publication Publication Date Title
ZA9610299B (en) Pyrazole derivatives process for their preparation and pharmaceutical compositions in which they are present
IL117598A (en) Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them
IL117265A0 (en) Benzazepine- benzoxazepine- and benzothiazepine-n-acetic acid derivatives their preparation and pharmaceutical compositions containing them
IL117193A0 (en) Poly-pyrrolecarbox-amidenaphthalenic acid derivatives their preparation and pharmaceutical compositions containing them
IL120141A (en) Substituted quinazoline derivatives process for their preparation and pharmaceutical compositions containing them
HUP9802300A3 (en) N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP0000562A3 (en) Fused pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
AU4666996A (en) Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
IL119559A0 (en) Purin -6- one derivatives their preparation and pharmaceutical compositions containing them
HUP9600071A3 (en) Indolo-piperidine derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9602635A3 (en) 4-aciloxy-benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP9600876A3 (en) Benzonitril- and -fluoride derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9702400A3 (en) Substituted camptothecin derivatives, process for their preparation and pharmaceutical compositions containing them
IL117331A (en) Indole derivatives their preparation and pharmaceutical compositions containing them
ZA9511029B (en) Substituted 4-phenylthiazole derivatives process for their preparation and pharmaceutical compositions containing them
HUP0002650A3 (en) 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]-indole-1-acetamide derivatives, process for their preparation and pharmaceutical compositions containing them
IL122377A (en) Anti-viral 5-benzoyl-1h-benzimidazoles, process for their preparation and pharmaceutical compositions containing them
HUP9601062A3 (en) Chromone derivatives, pharmaceutical compositions containing them and process for their preparation
IL116825A0 (en) Vitamin d derivatives their preparation and pharmaceutical compositions containing them
HUP9601751A3 (en) Benzothiopyran and thienothiopirane derivatives, process for their preparation and pharmaceutical compositions containing them
HUP9801068A3 (en) 1,2,3,4-tetrahydro-2-naphtaleneamine derivatives, process for their preparation, their use, and pharmaceutical compositions containing them
SG47476A1 (en) Heteroarylpiperidines process for their preparation and pharmaceutical compositions in which they are present
HUP9600173A3 (en) 4-amino-benzoyl-guanidine derivatives, process for preparing them and pharmaceutical compositions containing them
ZA963350B (en) Cycloheaxane compounds process for their preparation and pharmaceutical compositions containing them